Radiopharm Theranostics Advances with Promising PD-L1 Targeted Therapy Study

Radiopharm Theranostics Limited ((AU:RAD)) announced an update on their ongoing clinical study.

Study Overview: Radiopharm Theranostics Limited is conducting a Phase 0/1 study titled ‘Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients With Metastatic Solid Tumours.’ The study aims to assess the safety, tolerability, biodistribution, and preliminary anti-tumor activities of 177Lu-RAD204 in patients with metastatic solid tumors, identifying the maximum tolerated doses for future research.

Intervention/Treatment: The intervention being tested is 177Lu-RAD204, a radiolabelled single domain antibody designed to target PD-L1 in various solid tumors, including lung cancer and melanoma, to evaluate its potential as a treatment option.

Study Design: This interventional study follows a single-group model with no masking, focusing on treatment as its primary purpose. It includes a Phase 0 Imaging Period and a Phase 1 Treatment Period to assess the drug’s effects.

Study Timeline: The study began on February 22, 2024, with the latest update submitted on April 29, 2025. These dates are crucial as they mark the progression and current status of the study, which is still recruiting participants.

Market Implications: This study update could positively influence Radiopharm Theranostics’ stock performance by demonstrating progress in their clinical pipeline, potentially attracting investor interest. The development of 177Lu-RAD204 may also impact the competitive landscape in oncology therapeutics, particularly in targeting PD-L1.

The study is ongoing, and further details are available on the ClinicalTrials portal.